Abstract
Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED). The effects of several drugs on Hcy levels are also considered.
Folic acid, vitamin B6 and B12 supplementation can significantly decrease circulating Hcy concentrations but their effects on CVD risk reduction are conflicting. No current guidelines recommend the routine screening of Hcy levels in patients with non-cardiac vascular diseases. Therefore, further research is needed to elucidate the use of Hcy in the clinical practice.Keywords: Homocysteine, stroke, peripheral artery disease, carotid artery disease, chronic kidney disease, erectile dysfunction, vitamin B.
Current Pharmaceutical Design
Title:Homocysteine and Non-Cardiac Vascular Disease
Volume: 23 Issue: 22
Author(s): Niki Katsiki, Pablo Perez-Martinez and Dimitri P. Mikhailidis*
Affiliation:
- Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College London (UCL), Pond Street, London NW3 2QG,United Kingdom
Keywords: Homocysteine, stroke, peripheral artery disease, carotid artery disease, chronic kidney disease, erectile dysfunction, vitamin B.
Abstract: Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED). The effects of several drugs on Hcy levels are also considered.
Folic acid, vitamin B6 and B12 supplementation can significantly decrease circulating Hcy concentrations but their effects on CVD risk reduction are conflicting. No current guidelines recommend the routine screening of Hcy levels in patients with non-cardiac vascular diseases. Therefore, further research is needed to elucidate the use of Hcy in the clinical practice.Export Options
About this article
Cite this article as:
Katsiki Niki , Perez-Martinez Pablo and Mikhailidis P. Dimitri *, Homocysteine and Non-Cardiac Vascular Disease, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170317124913
DOI https://dx.doi.org/10.2174/1381612823666170317124913 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Craniofacial Fibrous Dysplasia Involvements of Mccune-Albright Syndrome: A Review with an Additional Case
Current Medical Imaging Injecting Illicit Substances Epidemic and Infective Endocarditis
Infectious Disorders - Drug Targets Management and Outcomes of Aortic Dissection in Pregnancy with Marfan Syndrome: A Systematic Review
Current Vascular Pharmacology Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Frequency of Thrombotic Events Among Adults Given Antifibrinolytic Drugs for Spontaneous Bleeding: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials
Current Drug Safety Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets Editorial [(Hot Topic Novel Drug Therapies in the Treatment of SAH) Guest Editors: Surya Karri and Christopher S. Ogilvy]
Current Drug Safety The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology Eye Disorders in Diabetes: Potential Drug Targets
Infectious Disorders - Drug Targets Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Meet Our Editorial Board Member
Current Vascular Pharmacology Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets